Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 5

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 5
---
 cash flow from operations;                                              |

| · | the Company’s ability to raise funding on reasonable terms as necessary to develop its products 
 in the timeframe contemplated by its business plan;                                             |

| · | the inability to maintain the listing of the Company’s common stock and warrants on Nasdaq following 
 the Business Combination;                                                                            |

| · | other risks and uncertainties indicated in this Report, including those under “Risk Factors”                                     
 beginning on page 26 in the Proxy Statement/Prospectus and other filings that have been made or will be made with the SEC by the 
 Company.                                                                                                                         |

In addition, there may be
events that the Company’s management is not able to predict accurately or over which the Company has no control.

<div align='center'>3</div>

Business

The business of the Company
is described in the Proxy Statement/Prospectus in the section titled “Business of Liminatus” beginning on page 184,
which is incorporated herein by reference.

Risk Factors

The risks associated with
the Company are described in the Proxy Statement/Prospectus, including those under “Risk Factors” beginning on page 26
in the Proxy Statement/Prospectus and specifically including in the sections titled “Risk Factors – Risks Related to Liminatus’s
Business and Operations” beginning on page 26 of the Proxy Statement/Prospectus, which are incorporated herein by reference.

Financial Information

The audited financial statements
of ParentCo for the fiscal years ended December 31, 2024 and 2023 are filed herewith as Exhibit 99.1.

The unaudited financial statements of ParentCo for the three months ended March 31, 2025 and 2024 are incorporated by reference to pages 1-8 in theQuarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed by ParentCo with
the SEC on May 30, 2025 (the “ParentCo Form 10-Q”).

The audited financial statements
of Liminatus for the fiscal years ended December 31, 2024 and 2023 are filed herewith as Exhibit 99.2.

The unaudited financial statements of Liminatus for the three
months ended March 31, 2025 and 2024 are filed herewith as Exhibit 99.5.

The audited financial statements
of Iris for the fiscal years ended December 31, 2024 and 2023 are incorporated